Roman V Kholodenko
Overview
Explore the profile of Roman V Kholodenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buzdin A, Heydarov R, Golounina O, Suntsova M, Matrosova A, Bondarenko E, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002253
Endogenous Cushing's syndrome (CS) is a rare neuroendocrine disorder characterized by either secondary cortisol increases due to an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor (Cushing's disease (CD)), an ACTH-secreting neuroendocrine tumor...
2.
Kim Y, Lupatov A, Burunova V, Bagmet N, Chardarov N, Malov S, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769138
Every 25th death worldwide is associated with liver pathology. The development of novel approaches to liver diseases therapy and protocols for maintaining the vital functions of patients on the liver...
3.
Svirshchevskaya E, Kostenko V, Boyko A, Shevtsov M, Kholodenko R, Grechikhina M, et al.
Nanomaterials (Basel)
. 2024 Dec;
14(23).
PMID: 39683266
Anti-cancer targeted therapy is a promising approach. However, the identification of target molecules over-expressed in a wide range of tumors remains a significant challenge. The aim of this study was...
4.
The Crosstalk between Mesenchymal Stromal/Stem Cells and Hepatocytes in Homeostasis and under Stress
Kholodenko I, Kholodenko R, Yarygin K
Int J Mol Sci
. 2023 Oct;
24(20).
PMID: 37894893
Liver diseases, characterized by high morbidity and mortality, represent a substantial medical problem globally. The current therapeutic approaches are mainly aimed at reducing symptoms and slowing down the progression of...
5.
Kalinovsky D, Kholodenko I, Svirshchevskaya E, Kibardin A, Ryazantsev D, Rozov F, et al.
Curr Issues Mol Biol
. 2023 Oct;
45(10):8112-8125.
PMID: 37886955
Oligomerization of antibody fragments via modification with polyethylene glycol (pegylation) may alter their function and properties, leading to a multivalent interaction of the resulting constructs with the target antigen. In...
6.
Kalinovsky D, Kholodenko I, Kibardin A, Doronin I, Svirshchevskaya E, Ryazantsev D, et al.
Int J Mol Sci
. 2023 Jan;
24(2).
PMID: 36674755
Ganglioside GD2 is a well-established target expressed on multiple solid tumors, many of which are characterized by low treatment efficiency. Antibody-drug conjugates (ADCs) have demonstrated marked success in a number...
7.
Kholodenko I, Kholodenko R, Majouga A, Yarygin K
Curr Issues Mol Biol
. 2022 Nov;
44(11):5153-5172.
PMID: 36354663
Over the past two decades, mesenchymal stem cells (MSCs) have shown promising therapeutic effects both in preclinical studies (in animal models of a wide range of diseases) and in clinical...
8.
Kim Y, Potashnikova D, Gisina A, Kholodenko I, Kopylov A, Tikhonova O, et al.
Int J Mol Sci
. 2022 Sep;
23(17).
PMID: 36077272
CD133 is an extensively studied marker of the most malignant tumor cell population, designated as cancer stem cells (CSCs). However, the function of this glycoprotein and its involvement in cell...
9.
Kholodenko I, Gisina A, Manukyan G, Majouga A, Svirshchevskaya E, Kholodenko R, et al.
Curr Issues Mol Biol
. 2022 Aug;
44(8):3428-3443.
PMID: 36005132
Mesenchymal stem cells (MSCs) have a pronounced therapeutic potential in various pathological conditions. Though therapeutic effects of MSC transplantation have been studied for a long time, the underlying mechanisms are...
10.
Kalinovsky D, Kibardin A, Kholodenko I, Svirshchevskaya E, Doronin I, Konovalova M, et al.
J Immunother Cancer
. 2022 Jun;
10(6).
PMID: 35764367
Background: Both ganglioside GD2-targeted immunotherapy and antibody-drug conjugates (ADCs) have demonstrated clinical success as solid tumor therapies in recent years, yet no research has been carried out to develop anti-GD2...